Показати скорочений опис матеріалу
dc.contributor.author | Drogovoz, S. | en |
dc.contributor.author | Kalko, K. | en |
dc.contributor.author | Borysiuk, I. | en |
dc.contributor.author | Barus, M. | en |
dc.contributor.author | Horoshko, V. | en |
dc.contributor.author | Svyshch, O. | en |
dc.contributor.author | Liulchak, S. | en |
dc.date.accessioned | 2023-01-31T10:19:43Z | |
dc.date.available | 2023-01-31T10:19:43Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Potential risks and pharmacological safety features of hypoglycemic drugs / S. Drogovoz, K. Kalko, I. Borysiuk et al. // PhOL. 2021. Vol. 2. P. 1164-1171. | en |
dc.identifier.uri | https://repo.odmu.edu.ua:443/xmlui/handle/123456789/12038 | |
dc.description.abstract | For the treatment of diabetes, insulin preparations, synthetic hypoglycemic agents, herbal medicine and compulsory adherence to the diet. Oral hypoglycemic agents belong to different chemical classes: sulfonylurea derivatives, biguanides, thiazolidinediones, etc. They can also be divided into secretogens (stimulate pancreatic insulin secretion, especially in the presence of glucose) and prandial (food - related) glycemic regulators (lower glucose in the blood after eating). As for the pharmacological safety of oral antidiabetic agents, they are incompatible with adrenal cortex hormones, adrenomimetics, MAO inhibitors, psychostimulants, antiarrhythmic agents. Their hypoglycemic effect is weakened by estrogens, gestagens, oral contraceptives, chlorpromazine, barbiturates, phenothiazines, thyroid hormones, glucagon, lithium salts, saluretics, indomethacin, drugs containing nicotinic acid. | en |
dc.language.iso | en | en |
dc.subject | hypoglycemic drugs | en |
dc.subject | potential risks | en |
dc.subject | pharmacological safety | en |
dc.title | Potential risks and pharmacological safety features of hypoglycemic drugs | en |
dc.type | Article | en |